CollPlant announces ‘successful’ results in 3D bioprinted breast implant study

CollPlant announced that it has successfully completed a large animal study for its recombinant human collagen-based 3D bioprinted regenerative breast implants, addressing the $2.5B global breast implant market. Supported by these promising results, the company is planning to initiate a follow-up large animal study during 2023 using commercial-size implants to support subsequent human studies and future product commercialization. The study demonstrated progressive stages of tissue regeneration as highlighted by the formation of maturing connective tissue and neovascular networks within the implants. No indication of adverse reaction was noted. Promising results support continued development of rhCollagen-based regenerative breast implants as a revolutionary and potentially safer and more natural alternative for aesthetic and reconstructive procedures, including postmastectomy for cancer patients.